Evotec SE (EVO) Net Cash Flow Growth (3y) (2022 - 2026)
Evotec SE (EVO) Net Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.85 Bn | 32.11 Bn | 1.97 Bn | 32.03% |
| 3 | Zoetis | 32.48 Bn | 30.54 Bn | 1.62 Bn | 28.99% |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn | 37.89% |
| 5 | United Therapeutics | 23.16 Bn | 21.01 Bn | 648.10 Mn | -49.94% |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.33 Bn | 18.53 Bn | 1.16 Bn | 37.74% |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.43 Bn | 800.70 Mn | -41.05% |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | -62.71% |
| 10 | Evotec SE | 346.28 Mn | 345.76 Mn | - | -85.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -85.81% |
| Dec 31, 2025 | 36.40% |
| Sep 30, 2025 | 24.78% |
| Jun 30, 2025 | -34.30% |
| Mar 31, 2025 | 23.32% |
| Dec 31, 2024 | -39.64% |
| Sep 30, 2024 | -48.77% |
| Jun 30, 2024 | -49.76% |
| Mar 31, 2024 | -84.47% |
| Dec 31, 2022 | -51.30% |